Drug Design Powered by AI, Driven by Biology
Mission Statement
With biology as our North Star, our mission is to integrate AI, computation, and biological automation to accelerate the design of small molecule and protein therapeutics.
- 1910Beginning
- 1976
- 1990
- 2003
- 2018
1st report of sicklecell anemia in theUnited States
We are
Backed By
Selected Investors
Platforms
We take a biology-first approach to disease target selection and subsequently apply ELVIS™ and ROSALYND™, our AI-driven computational platforms, to accelerate the design of both small molecule drugs and protein therapeutics. Our end-to-end technology powers the full length of early drug discovery, from novel hit discovery to hit-to-lead and lead optimization.
Want a deeper dive and more insight?
Check out our posts.
Have a look 
1910 Genetics Receives NIH Phase I STTR Grant for Discovery of Novel Non-Opioid Drugs for Chronic Pain
3m read 30th September, 2021.
1910 Genetics Debuts with $26M to Accelerate the Design of Small Molecule and Protein Therapeutics Through AI, Computation and Biological Automation
6m read 23rd March, 2021.